FDA Office of Orphan Products Development logo
Program

FDA Rare Neurodegenerative Disease Grants Program

Supports Clinical trial grants and contracts for ALS and other rare neurodegenerative diseases in adults and children.

FDA Office of Orphan Products DevelopmentUnited StatesGrant
About

The FDA Rare Neurodegenerative Disease Grants Program sits under the Office of Orphan Products Development and was established by the ACT for ALS Act in 2021. It began awarding grants in 2022 and supports clinical trial work on interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children.

The most recent notice had a re…

Industries covered
BiotechMedtechNeurotech
Grants under FDA Rare Neurodegenerative Disease Grants Program

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.

Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases
Between cycles

Funds clinical testing research for rare neurodegenerative disorders and therapeutic development.

— pool
Last verified: 29 May 2026Source: www.fda.gov